Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.

Financial CollaborationAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Bears Say

Cash ReservesThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Aptose Biosciences News

Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025

Aptose Biosciences ( ($TSE:APS) ) just unveiled an update. On November 3, 2025, Aptose Biosciences announced that an...

5d ago

Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment

Aptose Biosciences Inc. (($APTOF)) announced an update on their ongoing clinical study. Aptose Biosciences Inc. is conducting a...

12d ago

APTOF

Aptose’s Tuspetinib Shows Promising Results in AML Treatment Trial

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Biosciences announced promising results from its Phase 1/2...

24d ago

Aptose Secures $11.9M Loan for AML Therapy Development

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences has extended a loan agreement...

2M ago

Aptose Biosciences Announces Executive Retention Awards

Aptose Biosciences ( ($TSE:APS) ) just unveiled an announcement. On August 19, 2025, Aptose Biosciences Inc announced retention...

2M ago

Aptose Biosciences Secures Funding for Drug Development

Aptose Biosciences ( ($TSE:APS) ) has issued an update. On August 22, 2025, Aptose Biosciences held its reconvened...

3M ago

Aptose Biosciences Appoints New Independent Auditor

The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). On August 22, 2025, Aptose Biosciences announced...

3M ago

Aptose Biosciences Reports Positive Early Data from TUSCANY Trial for AML Treatment

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. Aptose Biosciences has reported promising early data from its...

3M ago

Aptose Biosciences Reports Promising Q2 2025 Results

Aptose Biosciences ( ($APTOF) ) has released its Q2 earnings. Here is a breakdown of the information Aptose...

3M ago

Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences announced its second quarter 2025...

3M ago

Aptose Biosciences shares to delist from Nasdaq as of April 2

Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the...

7M ago

APTO

Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2...

8M ago

APTO

Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year

“During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax...

8M ago

APTO

Aptose Biosciences meets Nasdaq minimum bid price compliance

Aptose Biosciences (APTO) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market notifying...

8M ago

APTO

APS FAQ

What was Aptose Biosciences’s price range in the past 12 months?

Aptose Biosciences lowest stock price was C$1.02 and its highest was C$17.40 in the past 12 months.

What is Aptose Biosciences’s market cap?

Aptose Biosciences’s market cap is $5.10M.

When is Aptose Biosciences’s upcoming earnings report date?

Aptose Biosciences’s upcoming earnings report date is Mar 24, 2026 which is in 135 days.

How were Aptose Biosciences’s earnings last quarter?

Currently, no data Available

Is Aptose Biosciences overvalued?

According to Wall Street analysts Aptose Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences pay dividends?

Aptose Biosciences does not currently pay dividends.

What is Aptose Biosciences’s EPS estimate?

Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptose Biosciences have?

Aptose Biosciences has 2,552,429 shares outstanding.

What happened to Aptose Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aptose Biosciences?

Currently, no hedge funds are holding shares in TSE:APS

Company Description

Aptose Biosciences

Aptose Biosciences Inc. (APS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of highly differentiated therapeutics addressing unmet medical needs in oncology. The company specializes in developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases. Aptose leverages a deep understanding of cancer biology to develop innovative small molecule cancer drugs.